Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Anti-Inflammatory Division Director Will Be Celebrex Investigator Simon

Executive Summary

Celebrex clinical investigator Lee Simon, MD, will take over as director of FDA's Division of Anti-Inflammatory, Analgesic & Ophthalmic Drug Products Nov. 19.
Advertisement

Related Content

Merck Vioxx Detailing Should Have Addressed VIGOR Risks – FDA’s Jenkins
Vioxx Label Balances CV Risk With GI Safety: Can Merck Reverse Damage?
Vioxx Label Balances CV Risk With GI Safety: Can Merck Reverse Damage?
Merck Vioxx Meningitis Case Reports Published By FDA Drug Safety Office
Merck Vioxx Meningitis Case Reports Published By FDA Drug Safety Office
Merck COX-2 Cardiovascular Safety Studies Will Enroll 30,000 Subjects
Pharmacia Bextra Will Test COX-2 Market; Valdecoxib Clears FDA Nov. 16
Pharmacia To Publish Full 12-Month Data From CLASS Study Of Celebrex
FDA Vaccines Office Head Midthun Joins From Analgesic Division
FDA Vaccines Office Head Midthun Joins From Analgesic Division
Advertisement
UsernamePublicRestriction

Register

PS038437

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel